Tissue Repair
KPV
Lys-Pro-Val; α-MSH(11-13)
Tripeptide; α-MSH-derived anti-inflammatory
This KPV entry draws on 1 cited source published 2008. The evidence available is graded Preclinical + Anecdotal on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .
At a glance
- Class
- Tripeptide; α-MSH-derived anti-inflammatory
- Drug class
- Tissue Repair
- Structure
- Tripeptide Lys-Pro-Val; C-terminal fragment of α-MSH
- Route
- Oral / SC / Topical
- Half-life
- Minutes (plasma)
- Evidence tier
- Preclinical + Anecdotal
- Availability
- Research
- Research depth
- 197 indexed citations →
Mechanism of action
Inhibits NF-κB; stabilizes mast cells; reduces pro-inflammatory cytokines; mimics α-MSH C-terminus
Reported areas of research
Potent anti-inflammatory; mast cell stabilization; gut barrier repair; IBD/colitis benefit; skin inflammation
Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.
Dosage protocols reported in literature
200 mcg daily oral or SC (anti-inflammatory starting dose for IBD and skin support, range up to 500 mcg/day per r/Peptides wiki); topical 0.1-1%
Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.
Known concerns and limitations
Limited human data; oral bioavailability uncertain
Compared with
KPV has published head-to-head comparisons with 2 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.
Frequently asked questions
What dosing is reported for KPV in research literature?
Published peptide research reports the following dosing approach for KPV: 200 mcg daily oral or SC (anti-inflammatory starting dose for IBD and skin support, range up to 500 mcg/day per r/Peptides wiki); topical 0.1-1%. This is a research reference, not a clinical recommendation.
How is KPV administered in research?
KPV is administered via the following routes in published studies: Oral / SC / Topical.
What is the reported half-life of KPV?
No measured half-life for KPV is reported in the literature catalogued here. The catalog describes it as: Minutes (plasma).
Is KPV FDA-approved?
No. KPV is not an FDA-approved drug. KPV was nominated for FDA's bulk drug substance lists, flagged by FDA for possible safety risks, and the nomination was then withdrawn by the party that filed it, which leaves it with no route to lawful compounding rather than with a clean record. On 23 July 2026 FDA's Pharmacy Compounding Advisory Committee (docket FDA-2025-N-6895) voted 8 for, 6 against, 1 abstention to recommend KPV for the 503A Bulks List, for wound healing and inflammatory conditions. The vote is advisory: it adds nothing to the list by itself, and an addition would require a proposed rule, a public comment period and a final rule. PeptideHelper.org catalog status: Research.
Sources: FDA: bulk drug substances that may present significant safety risks; FDA meeting notice and agenda; Fierce Pharma, 23 July 2026; Pharmaceutical Executive, 24 July 2026.
What level of evidence supports KPV?
The current evidence base for KPV is best characterised as: Preclinical + Anecdotal. See the methodology page for the full evidence-tier rubric.
What side effects are reported for KPV?
Known concerns reported in the literature for KPV include: Limited human data; oral bioavailability uncertain. Always consult a qualified clinician before any human use.
Is there anyone who should not use KPV?
No formal contraindications are established for KPV, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: Limited human data; oral bioavailability uncertain. Always consult a qualified clinician before any human use.
How does KPV work?
The mechanism of action reported for KPV in the literature: Inhibits NF-κB; stabilizes mast cells; reduces pro-inflammatory cytokines; mimics α-MSH C-terminus.
What is KPV studied for?
KPV has been studied in the published literature for: Potent anti-inflammatory; mast cell stabilization; gut barrier repair; IBD/colitis benefit; skin inflammation. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.
What is KPV?
KPV is classified as: Tripeptide; α-MSH-derived anti-inflammatory. Also known as: Lys-Pro-Val; α-MSH(11-13).
Studied in combination
KPV appears in the following peptide combinations discussed in research and practitioner literature:
- GLOW / KLOW, Tissue repair, anti-inflammation, skin regeneration
Drug class
- Anti-inflammatory peptides, see all peptides tagged Anti-inflammatory.
Research focus area
All peptides studied for Tissue Repair, ranked by evidence tier and regulatory status.
Primary sources
Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.
Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.
Loading interactive view…